CEO: Michael Engsig

Web: Nykode Therapeutics

Established in: 2006


CEO: Jan Alfheim

Website: Oncoinvent

Established in: 2010


CEO: Geir Åge Løset

Web: Nextera

Established in: 2009


CEO: Daniel Schneider

Web: Photocure

Established in: 1993

PCI Biotech

Established in: 2000

CEO: Ronny Skuggedal 

Web: PCI Biotech


Established in: 2010

CEO: Erik Digman Wiklund 

Web: Targovax 


Established in: 2011

CEO: Carlos de Sousa

Web: Ultimovacs

Established in: 2016

CEO: Namir Hassan

Web: Zelluna 

Established in: 2018

CEO: Jon Amund Eriksen

Web: Hubro Therapeutics 

Established in: 2016

CEO: Einar Martin Aandahl

Web: Ledidi

Adjutec Pharma sin logo

Established in: 2019

CEO: Bjørn Klem 

Web: AdjuTec Pharma


Established in: 2014

CEO: Richard Stratford


NEC OncoImmunity AS is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy.

NEC OncoImmunity AS is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in a clinically actionable time-frame.

NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway. The company was formerly named OncoImmunity AS.  NEC Corporation, a global Japanese technology company, acquired OncoImmunity AS in July 2019, and hence the name changed to NEC OncoImmunity AS.

RADFORSK started to work with OncoImmunity AS in 2015 and were behind the first share issue in 2016. RADFORSK was deeply involved in the company’s development until the acquisition in 2019 as its biggest owner. Mr. Anders Tuv, Investment Director Radforsk, was Chairman of the Board until the acqusition, and was in charge of the sales process in relation to NEC Corporations.